Medicare Will Pay for Zepbound for Some Patients. The Costs Could be Huge
The cost to taxpayers could be enormous.Sales growth of Zepbound in the U.S. has been constrained by rules that bar Medicare, ...
Hosted on MSN56m
NVO Stock Up 3% as UBS Upgrades Company Rating From Neutral to Buy
Shares of Novo Nordisk NVO gained 2.8% on Wednesday likely because the analysts at UBS upgraded the company’s rating from ...